Clinical Trial

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase II clinical trial. Patients will receive intensity modulated total body irradiation (TBI) at a dose of 3 Gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (HLA)-haploidentical hematopoietic stem cell transplant (HSCT). The primary objective of the study is to determine the engraftment at Day +60 following HLA-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (TBI) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05 -> 2029-05 2026-07-09
minor Completion pushed: 2026-05 -> 2029-05 2026-07-09
Trial Details
NCT Number NCT03121001
Lead Sponsor University of Illinois at Chicago
Conditions Sickle Cell Disease
Enrollment 50 participants
Start Date 2017-03-20
Primary Completion 2029-05 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-08